Sy Mukherjee, Fortune

Sy Mukherjee

Fortune

New York, NY, United States

Contact Sy

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

Recent:
  • Unknown
Past:
  • Fortune

Past articles by Sy:

Intellia stock: What the CRISPR biotech's success means for the gene-editing industry

A groundbreaking CRISPR treatment from Intellia Therapeutics sent the company's stock soaring and could lift the entire gene-editing industry's prospects by transforming DNA inside of a human body. → Read More

The COVID Delta variant is infecting some fully vaccinated adults in Israel. Should you be worried?

A number of Israeli adults who were fully vaccinated with Pfizer's COVID vaccine were infected by the Delta variant. But the issue comes with plenty of nuance. → Read More

Articles by Sy Mukherjee

© 2020 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell My Personal Information | Ad Choices FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services… → Read More

The secret to checking items off the corporate to-do list? Decluttering, says Poo~Pourri CEO

"I want more clarity and communication," says Poo~Pourri and Supernatural CEO and founder Suzy Batiz at Fortune's MPW Next Gen conference. And she means in every aspect of business from emails to office space. → Read More

The delta between the Delta variants

There's another new COVID variant that has the potential to wreak havoc. The key word there is "potential." → Read More

A mutation of a mutation: What you need to know about the COVID Delta Plus variant

There's yet another COVID mutation that's spreading in certain countries. But just how concerned should the world be about the Delta Plus variant? → Read More

The U.S. won’t make the President’s July 4 vaccination target. Here’s what that means

The White House admits we won't hit 70% of adults with at least one COVID shot by the 4th of July - but just barely. → Read More

Pressure mounts on Biden to nominate permanent FDA head as dissatisfaction with agency grows

Sen. Joe Manchin is taking a tough stance against acting FDA chief Janet Woodcock following Biogen's controversial Alzheimer's drug approval. But we still don't know who President Biden will appoint to the permanent position. → Read More

3 Black diversity chiefs on how they’ll fight racial inequality in medicine

On this Juneteenth, the chief diversity, equity, and inclusion officers of Pfizer, UnitedHealth Group, and Kaiser Permanente tell Fortune how they plan to tangibly address health inequality in Black communities. → Read More

Three Black health care diversity officers. One united goal

Black chief diversity officers discuss health inequality in medicine and what they want to do about it. → Read More

The decade-long battle against Obamacare reaches a likely end with new Supreme Court decision

On Thursday, the Supreme Court hammered what is likely the final nail in the coffin for Obamacare foes. → Read More

What you should know about the Delta variant and what it means for re-opening

The COVID delta variant strain is a growing concern as it could lead to more serious illness and coronavirus infections, according to the CDC. → Read More

What we know about COVID vaccines, heart inflammation, and its implications for drug makers

The CDC is convening an emergency meeting after rare cases of heart swelling in those who received mRNA-based COVID vaccines. Here's what we know and what it means for the industry. → Read More

What comes next after the Biogen Alzheimer’s drug approval

Biogen's Alzheimer's drug approval could pave the way for major changes across the industry. → Read More

Biogen won its controversial Alzheimer’s drug approval. Which drugmakers will see the next big win?

With the precedent set, the FDA's decision to approve Biogen's Alzheimer's drug could cause ripple effects across the industry in multiple diseases. → Read More

FDA approves historic Biogen Alzheimer's drug aducanumab—marketed as Aduhelm—the first treatment of its kind.

The FDA on Monday granted a historic approval to Biogen's closely-watched, and highly controversial, Alzheimer's drug aducanumab, the first treatment of its kind. → Read More

The health care companies leading 2021’s Fortune 500 list

Health care companies across the gamut of the industry scored big in the 2021 Fortune 500 list. → Read More

Abortion, Obamacare, and drug approvals: American health care faces a pivotal moment

From to the future of Obamacare to abortion rights to drug approvals, we're at a pivotal moment in American health care policy. → Read More

The U.S. military had a COVID vaccine skepticism problem. But now it’s seeing a massive jump in shots

COVID vaccinations among the U.S. military have jumped 55% in the past month, a remarkable turnaround given many servicemembers' hesitancy about the vaccine. → Read More

Congress loves a Big Pharma villain. But will that lead to any real policy changes on drug prices?

AbbVie has never been shy about guarding its patents and hiking drug prices. Congress tore into the company this week. But will it lead to any real policy change? → Read More